TipRanks
Go Ultimate55% OFF

Victrex (VTXPF) AI Stock Analysis

1 Followers
VTXPF

Victrex

(Other OTC:VTXPF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Specialty materials positioningVictrex operates in specialized, performance-critical materials where heat, chemical, strength-to-weight and wear resistance can make substitution difficult. Its resin, films, fibers and semi-finished forms support differentiated applications and specialty pricing across diverse industrial and regulated end-markets.
Negative Factors
Revenue contractionA decline in revenue indicates that current demand and end-market activity are not yet translating into sustained top-line expansion. If this persists, slower scale growth could limit operating leverage, reduce investment capacity and make it harder for Victrex to compound earnings over coming quarters.

Victrex (VTXPF) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%VTXPF+59.11%SPY+10.42%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$793.57M
Dividend Yield
6.99%
Average Volume (3M)
694
Price to Earnings (P/E)
-39.6
Beta (1Y)
0.18
Revenue Growth
3.74%
EPS Growth
-169.28%
Country
US
Employees
1,169
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Victrex Business Overview & Revenue Model

Company Description

Operating globally through its subsidiaries, Victrex plc is a specialized producer and distributor of polymer materials. The company organizes its business into two core divisions: Industrial and Medical. It concentrates on creating PEEK and PAEK pol...

Victrex Earnings Call Summary

Earnings Call Date:Dec 01, 2025(Q4-2025)|% Change Since:61.13%|Next Earnings Date:Dec 07, 2026
Earnings Call SentimentNeutral

The earnings call presented a mixed picture with notable achievements in volume growth and cash conversion, while facing significant challenges due to currency impacts, weaker medical spine performance, and losses from the China facility. The profit improvement plan and diversification in medical revenues are positive steps, but current financial challenges weigh heavily.

Positive Updates

Strong Volume Growth
Sales volume increased by 12% to 4,164 tonnes, primarily driven by value-added resellers and Energy & Industrial sectors.

Negative Updates

Currency Impact on Profit
Underlying profit before tax was adversely affected by GBP 8 million due to currency impacts, contributing to a 21% decrease in PBT.

Company Guidance

In the call, Victrex provided guidance on various financial metrics for fiscal year 2025 and the outlook for 2026. The company reported a 12% increase in sales volume, reaching 4,164 tonnes, mainly driven by value-added resellers (VARs) and the Energy & Industrial sector. Despite the robust volume growth, underlying profit before tax (PBT) was impacted by an adverse currency effect of GBP 8 million, resulting in a 21% decrease to GBP 46.4 million. However, cash conversion was strong at 121%, benefiting from efficient working capital management. Capital expenditures (CapEx) saw a significant reduction, reflecting the conclusion of recent investment phases. For fiscal 2026, Victrex is targeting low to mid-single-digit volume growth and aims to achieve at least GBP 10 million in savings through a profit improvement plan. Gross margin for FY '26 is expected to be flat to slightly ahead, with the China manufacturing facility remaining a focus for operational improvements. The company will maintain its dividend and review its capital allocation policy, aiming to retain a strong balance sheet with a net debt-to-EBITDA range of 0.5x to 1x.

Victrex Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

VTXPF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:ELMGB:ELM73OutperformGBP 1.09B20.1511.29%1.72%-11.73%―
GB:ZTFGB:ZTF68NeutralGBP 222.30M8.9318.18%1.79%14.35%3370.14%
GB:CRDAGB:CRDA66NeutralGBP 5.04B64.553.65%3.04%3.36%-43.08%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
GB:SYNTGB:SYNT60NeutralGBP 180.34M-1.49-13.27%―-4.98%-43.98%
GB:ESNTGB:ESNT53NeutralGBP 318.80M60.002.02%1.84%6.98%-41.36%

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%150%VTXPFGB:CRDAGB:ELMGB:ESNTGB:SYNTGB:ZTFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VTXPF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VTXPFVictrex plc12.284.6260.25%
GB:CRDACroda International3651.00974.8136.43%
GB:ELMElementis plc194.0037.9324.30%
GB:ESNTEssentra plc114.0022.9125.16%
GB:SYNTSynthomer plc109.2063.15137.13%
GB:ZTFZotefoams plc446.5083.6623.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.